Evidence map›Paper›PMID 31637624›Full record

ReviewCurrent obesity reports2019

The Role of Adipokines in Breast Cancer: Current Evidence and Perspectives.

Gerasimos Socrates Christodoulatos, Nikolaos Spyrou, Jona Kadillari, Sotiria Psallida, Maria Dalamaga

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current obesity reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed, 1 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 1 synthesis or guideline pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Targeting breast tumor extracellular matrix and stroma utilizing nanoparticles.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Gerasimos Socrates ChristodoulatosDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias, Goudi, 11527, Athens, Greece.
Nikolaos Spyrou251 Airforce General Hospital, 3 Kanellopoulou, 11525, Athens, Greece.
Jona KadillariDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias, Goudi, 11527, Athens, Greece.
Sotiria PsallidaLaboratory of Microbiology, KAT Hospital, 2 Nikis, Kifisia, 14561, Athens, Greece.
Maria DalamagaDepartment of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias, Goudi, 11527, Athens, Greece. madalamaga@med.uoa.gr.
General Hospital of Attica · GRNational and Kapodistrian University of Athens · GRHellenic Airforce General Hospital · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe current review shows evidence for the role of adipokines in breast cancer (BC) pathogenesis summarizing the mechanisms underlying the association between adipokines and breast malignancy. Special emphasis is given also on intriguing insights into the relationship between obesity and BC as well as on the role of novel adipokines in BC development. RECENT

findingsRecent evidence has underscored the role of the triad of obesity, insulin resistance, and adipokines in postmenopausal BC. Adipokines exert independent and joint effects on activation of major intracellular signal networks implicated in BC cell proliferation, growth, survival, invasion, and metastasis, particularly in the context of obesity, considered a systemic endocrine dysfunction characterized by chronic inflammation. To date, more than 10 adipokines have been linked to BC, and this catalog is continuously increasing. The majority of circulating adipokines, such as leptin, resistin, visfatin, apelin, lipocalin 2, osteopontin, and oncostatin M, is elevated in BC, while some adipokines such as adiponectin and irisin (adipo-myokine) are generally decreased in BC and considered protective against breast carcinogenesis. Further evidence from basic and translational research is necessary to delineate the ontological role of adipokines and their interplay in BC pathogenesis. More large-scale clinical and longitudinal studies are awaited to assess their clinical utility in BC prognosis and follow-up. Finally, novel more effective and safer adipokine-centered therapeutic strategies could pave the way for targeted oncotherapy.

Indexed as

AdipokinesAdiponectinAdipose TissueAnimalsApelinBreast NeoplasmsCell ProliferationCytokinesFemaleFibronectinsHumansInflammationLeptinLipocalin-2Nicotinamide PhosphoribosyltransferaseObesityAdipokinesAdiponectinADIPOQ protein, humanApelinAPLN protein, humanCytokinesFibronectinsFNDC5 protein, humanLCN2 protein, humanLEP protein, humanLeptinLipocalin-2Nicotinamide Phosphoribosyltransferasenicotinamide phosphoribosyltransferase, humanOncostatin MOsteopontinResistinRETN protein, humanSPP1 protein, humanAdipokineAdiponectinApelinBreast cancerChemerinIrisinLeptinLipocalin 2Nicotinamide phosphoribosyl-transferaseObesityOmentinOncostatin MOsteopontinResistinVisfatin

Identifiers

PMID31637624
OpenAlexW2981320413

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.